Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
2020
Objective: To assess the cost-effectiveness of pembrolizumab monotherapy compared with standard chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in previously untreated...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
18
References
6
Citations
NaN
KQI